ReviewMethods in molecular biology (Clifton, N.J.)2022
Target Discovery for Drug Development Using Mendelian Randomization.
Review in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Mendelian Randomization Studies of Major Depressive Disorder, Schizophrenia, Bipolar Disorder, and Cancers: A PRISMA Review and Meta-Analysis.Endocrine, metabolic & immune disorders drug targets · 2026Pooled it
- Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.Frontiers in endocrinology · 2024Pooled it
- Multiomics integration prioritizes potential drug targets for lung cancer.Discover oncology · 2026Article
- Association of antihypertensive drugs, intestinal ischemia, and breast diseases: A drug-target Mendelian Randomization study.Medicine · 2026Article
- Screening of Natural Inhibitors fromACS omega · 2026Article
- Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma.Frontiers in pharmacology · 2026Article
- Association between lipid-lowering drug targets and the risk of cystic kidney disease: a drug-target Mendelian randomization analysis.Renal failure · 2025Article
- Leveraging genetic data for female breast cancer prevention and therapy: Perspectives from Mendelian randomization.iMetaOmics · 2025Article
- Article
- Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment.Clinical proteomics · 2025Article
- Identification of Potential Therapeutic Targets for Sensorineural Hearing Loss and Evaluation of Drug Development Potential Using Mendelian Randomization Analysis.Bioengineering (Basel, Switzerland) · 2025Article
- UDP-Glucose Ceramide Glucosyltransferase Inhibition, Immune Cell Mediation, and Endometriosis Risk: A Mendelian Randomization Study.International journal of women's health · 2025Article
- Exploration of protein and genetic targets causing atrioventricular block: mendelian-randomization analyses based on eQTL data and pQTL data.BMC cardiovascular disorders · 2024Article
- Genetic association of lipid-lowering drug target genes with erectile dysfunction and male reproductive health.Frontiers in endocrinology · 2024Article
- Article
- Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.Lipids in health and disease · 2023Article
- Genetic and Gene Expression Resources for Osteoporosis and Bone Biology Research.Current osteoporosis reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Making drug development more efficient by identifying promising drug targets can contribute to resource savings. Identifying promising drug targets using human genetic approaches can remove barriers related to translation. In addition, genetic information can be used to identify potentially causal relationships between a drug target and disease. Mendelian randomization (MR) is a class of approaches used to identify causal associations between pairs of genetically predicted traits using data from human genetic studies. MR can be used to prioritize candidate drug targets by predicting disease outcomes and adverse events that could result from the manipulation of a drug target. The theory behind MR is reviewed, including a discussion of MR assumptions, different MR analytical methods, tests for violations of assumptions, and MR methods that can be robust to some violations of MR assumptions. A protocol to perform two-sample MR (2SMR) with summary genome-wide association study (GWAS) results is described. An example of 2SMR examining the causal relationship between low-density lipoprotein (LDL) and coronary artery disease (CAD) is provided as an illustration of the protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.